25 May 2013
Keywords: update, via-2291, ongoing, ph, ii, program, via
Article | 14 April 2008
VIA Pharmaceuticals , a US biotechnology company focused on the development of compounds for the treatment of cardiovascular disease,
says that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
24 May 2013
© 2013 thepharmaletter.com